Last reviewed · How we verify
Aliskiren 3.125 mini-tablets
Aliskiren is a direct renin inhibitor that blocks the conversion of angiotensinogen to angiotensin I, reducing blood pressure.
Aliskiren is a direct renin inhibitor that blocks the conversion of angiotensinogen to angiotensin I, reducing blood pressure. Used for Hypertension.
At a glance
| Generic name | Aliskiren 3.125 mini-tablets |
|---|---|
| Sponsor | Novartis |
| Drug class | Renin inhibitor |
| Target | Renin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 1 |
Mechanism of action
By inhibiting renin, aliskiren reduces the production of angiotensin II, which leads to vasodilation and decreased aldosterone secretion, ultimately lowering blood pressure.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aliskiren 3.125 mini-tablets CI brief — competitive landscape report
- Aliskiren 3.125 mini-tablets updates RSS · CI watch RSS
- Novartis portfolio CI